HIV Protocols pp 427-433 | Cite as

Isolation of Drug-Resistant Mutant HIV Variants Using Tissue Culture Drug Selection

  • Maureen Oliveira
  • Bluma G. Brenner
  • Mark A. Wainberg
Part of the Methods In Molecular Biology™ book series (MIMB, volume 485)


The life cycle of HIV-1 can be affected in different manners by the various classes of antiviral agents. Genetic heterogeneity is a characteristic of this virus, which contributes significantly to the ability of the virus to generate mutations which overcome the efficacy of the drug therapy. The selection of drug resistant mutants in vitro can be readily accomplished by maintaining the virus in a state of sub-optimal growth, regulated by slowly increasing the amount of drug pressure applied. This technique is thought to mimic the consequences of drug therapy in patients. Therefore, in this way, novel compounds can be assessed for their selection profile in order to preview the likelihood of emergence of HIV-1 drug resistance in future clinical trials. In addition, combinations of drugs can be investigated in the same manner.

Key words

HIV-1 drug selection drug resistance resistance mutations 


  1. 1.
    Gao, Q., Gu, Z., Parniak, M.A., et al. (1992) In Vitro Selection of Human Immunodeficiency Virus Type I Resistant to \(3^{-}\)-Azido-\(3^{-}\)-Deoxythymidine and \(2^{-},3^{-}\)-Dideoxynosine. J Virol 66, 12–19PubMedGoogle Scholar
  2. 2.
    Gao., Q., Gu, Z., Salomon, H., et al. (1994) Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1. Arch Virol 136, 111–122CrossRefPubMedGoogle Scholar
  3. 3.
    Richman, D., Shih, C-K., Lowy, I., et al. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 88, 11241–11245CrossRefPubMedGoogle Scholar
  4. 4.
    Larder, B., Kellam, P., Kemp, S. (1993) Convergent combination therapy can select viable multidrug- resistant HIV-1 in vitro. Nature 365, 451–453CrossRefPubMedGoogle Scholar
  5. 5.
    Diallo, K., Brenner B., Oliveira, M., et al.. (2003) The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob Agents Chemother July, 2376–2379Google Scholar
  6. 6.
    Wainberg MA, Brenner BG, Turner D. (2005)Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49(5), 1671–1678,.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Maureen Oliveira
    • 1
  • Bluma G. Brenner
    • 1
  • Mark A. Wainberg
    • 1
  1. 1.McGill University AIDS Centre Lady Davis Institute for Medical ResearchJewish General HospitalMontrealCanada

Personalised recommendations